Hypoparathyroidism: Replacement Therapy with Parathyroid Hormone.
10.3803/EnM.2015.30.4.436
- Author:
Lars REJNMARK
1
;
Line UNDERBJERG
;
Tanja SIKJAER
Author Information
1. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark. rejnmark@clin.au.dk
- Publication Type:Review
- Keywords:
Hypoparathyroidism;
Calcium;
Vitamin D;
Parathyroid hormone treatment
- MeSH:
Calcium;
Comorbidity;
Homeostasis;
Humans;
Hypoparathyroidism*;
Parathyroid Hormone*;
Physiology;
Quality of Life;
Vitamin D
- From:Endocrinology and Metabolism
2015;30(4):436-442
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hypoparathyroidism (HypoPT) is characterized by low serum calcium levels caused by an insufficient secretion of parathyroid hormone (PTH). Despite normalization of serum calcium levels by treatment with activated vitamin D analogues and calcium supplementation, patients are suffering from impaired quality of life (QoL) and are at increased risk of a number of comorbidities. Thus, despite normalization of calcium levels in response to conventional therapy, this should only be considered as an apparent normalization, as patients are suffering from a number of complications and calcium-phosphate homeostasis is not normalized in a physiological manner. In a number of recent studies, replacement therapy with recombinant human PTH (rhPTH(1-84)) as well as therapy with the N-terminal PTH fragment (rhPTH(1-34)) have been investigated. Both drugs have been shown to normalize serum calcium while reducing needs for activated vitamin D and calcium supplements. However, once a day injections cause large fluctuations in serum calcium. Twice a day injections diminish fluctuations, but don't restore the normal physiology of calcium homeostasis. Recent studies using pump-delivery have shown promising results on maintaining normocalcemia with minimal fluctuations in calcium levels. Further studies are needed to determine whether this may improve QoL and lower risk of complications. Such data are needed before replacement with the missing hormone can be recommended as standard therapy.
